JNK2/MKK7 PPI-IN-1

JNK2/MKK7 PPI-IN-1 是一种口服活性的 JNK2 抑制剂(IC50 为 0.99 μM,Kd 为 81.6 μM),可抑制 JNK2 激酶活性、破坏 JNK2-MKK7 蛋白-蛋白相互作用并降低 c-Jun 磷酸化水平,同时抑制 LPS 诱导的炎性细胞因子 IL-6 和 TNF-α 过表达,可用于急性肺损伤的相关研究。
JNK2/MKK7 PPI-IN-1
产品编号: MS-Z66495 分子式: C26H25N3O5 分子量: 459.49
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

JNK2/MKK7 PPI-IN-1 是一种口服活性的 JNK2 抑制剂(IC50 为 0.99 μM,Kd 为 81.6 μM),可抑制 JNK2 激酶活性、破坏 JNK2-MKK7 蛋白-蛋白相互作用并降低 c-Jun 磷酸化水平,同时抑制 LPS 诱导的炎性细胞因子 IL-6 和 TNF-α 过表达,可用于急性肺损伤的相关研究。

生物实验数据

生物活性 JNK2/MKK7 PPI-IN-1 is an orally active JNK2 inhibitor (IC50 = 0.99 μM, Kd = 81.6 μM) that inhibits JNK2 kinase activity, disrupts the JNK2-MKK7 protein-protein interaction, reduces c-Jun phosphorylation, suppresses LPS-induced overexpression of the inflammatory cytokines IL-6 and TNF-α, and can be used for research related to acute lung injury.
IC50 & Target

JNK2

0.99 μM (IC50)

JNK2

81.6 μM (Kd)

IL-6

 

体外研究
(In Vitro)

JNK2/MKK7 PPI-IN-1 (6l) (0.08-10 μM; 24 h) 可抑制 J774A.1 巨噬细胞 (IC50 = 2.78 μM) 和 THP-1 巨噬细胞 (IC50 = 0.14 μM) 中 LPS 诱导的 IL-6 分泌,并抑制 J774A.1 巨噬细胞 (IC50 = 0.55 μM) 中 TNF-α 的分泌。
JNK2/MKK7 PPI-IN-1 (5, 10 μM; 24 h) 可抑制 RAW 264.7 巨噬细胞中 LPS 诱导的 IL-6 和 TNF-α mRNA 表达。
JNK2/MKK7 PPI-IN-1 (0.125-4 μM) 抑制 JNK2 激酶活性,IC50 为 0.99 μM。
JNK2/MKK7 PPI-IN-1 (20-60 μM) 破坏 JNK2 和 MKK7 之间的相互作用,通过共免疫沉淀实验证实。
JNK2/MKK7 PPI-IN-1 (6.25-200 μM) 与 JNK2 结合,通过表面等离子共振 (SPR) 测定,Kd 为 81.6 μM。
JNK2/MKK7 PPI-IN-1 (10 μM) 可稳定完整 RAW 264.7 细胞中的 JNK2 蛋白,使其免受热变性。
JNK2/MKK7 PPI-IN-1 (0.2-5 μM; 24 h) 可抑制 LPS 诱导的 c-Jun、p38 和 p65 的磷酸化,并维持 RAW 264.7 巨噬细胞中 IκBα 蛋白的水平。
JNK2/MKK7 PPI-IN-1 (5 μM; 24 h) 通过免疫荧光染色观察到可抑制 LPS 诱导的 c-Jun 核转位。

ELISA Assay

Cell Line: RAW 264.7 macrophages
Concentration: 10 μM (pre-incubation for LPS-induced IL-6 inhibition); 0.08, 0.4, 2, 10 μM (dose-response testing)
Incubation Time: 0.5 h (pre-incubation); 24 h (LPS stimulation)
Result: Inhibited LPS-induced IL-6 production by 86.86% at 10 μM, with an IC50 of 0.32 μM in a dose-dependent manner.

Real Time qPCR

Cell Line: RAW 264.7 macrophages
Concentration: 5, 10 μM
Incubation Time: 3 h (pre-incubation); 6 h (LPS stimulation)
Result: Significantly suppressed LPS-induced elevations in IL-6 and TNF-α mRNA levels in a dose-dependent manner.

Immunofluorescence

Cell Line: RAW 264.7 macrophages
Concentration: 10 μM
Incubation Time: 2 h (pre-incubation); 30 min (LPS stimulation)
Result: Significantly suppressed LPS-induced nuclear translocation of c-Jun.

Western Blot Analysis

Cell Line: RAW 264.7 macrophages
Concentration: 0.2 μM, 1 μM, 5 μM
Incubation Time: 2 h (pre-incubation); 30 min (LPS stimulation)
Result: Inhibits LPS-induced phosphorylation of c-Jun, p38, and p65; preserves IκBα protein level compared to LPS-treated group.
体内研究
(In Vivo)

JNK2/MKK7 PPI-IN-1 (20 mg/kg;灌胃;每 12 小时给药 1 次,共 3 次) 可显著减轻 LPS (MS-X54539) 诱导的小鼠急性肺损伤 (ALI) 模型中的肺水肿、肺泡通透性增加及炎性细胞因子产生,还能显著缓解 CLP 诱导的小鼠 ALI 模型中的肺水肿、肺泡损伤及炎性细胞因子产生。
JNK2/MKK7 PPI-IN-1 (500 mg/kg;灌胃;单次给药) 在雄性 C57BL/6 小鼠中表现出良好的急性安全性,未出现死亡、器官损伤或持续性体重下降。
JNK2/MKK7 PPI-IN-1 (100 mg/kg;灌胃;每日一次;连续 14 天) 在雄性 C57BL/6 小鼠中表现出良好的亚急性安全性,未出现死亡、器官损伤或显著的肝酶升高现象。

Animal Model: C57BL/6 (male, 18-22 g, LPS-induced ALI)
Dosage: 20 mg/kg
Administration: p.o.; three doses at 12-hour intervals
Result: Significantly attenuated LPS-induced pulmonary edema (reduced lung wet/dry weight ratio).
Decreased protein concentration and total cell counts in bronchoalveolar lavage fluid (BALF).
Reduced IL-6 levels in both serum and BALF.
Alleviated LPS-induced splenomegaly.
Reduced lung tissue damage, neutrophil influx, and macrophage infiltration compared to LPS-only controls.
Reduced splenic histopathological changes compared to LPS-only controls.
Animal Model: C57BL/6 (male, 18-22 g, CLP-induced sepsis ALI)
Dosage: 20 mg/kg
Administration: p.o.; three doses at 12-hour intervals
Result: Significantly reduced CLP-induced pulmonary edema (lower lung wet/dry weight ratio compared to CLP-only controls).
Decreased protein concentration and total cell counts in BALF.
Reduced IL-6 and IL-1β levels in BALF.
Ameliorated CLP-induced splenomegaly.
Reduced lung tissue injury, inflammatory cell infiltration, and alveolar septal thickening compared to CLP-only controls.
Reduced splenic white pulp fusion compared to CLP-only controls.
Animal Model: C57BL/6 (male, 18-22 g)
Dosage: 500 mg/kg
Administration: p.o.; single dose
Result: Observed no mortality or abnormal behaviors.
Showed an initial slight decrease in body weight, followed by gradual recovery to levels comparable to controls.
Showed no significant organ damage in heart, liver, spleen, lung, or kidney tissues via histopathological analysis.
Animal Model: C57BL/6 (male, 18-22 g)
Dosage: 100 mg/kg
Administration: p.o.; daily; 14 days
Result: Observed no mortality or abnormal behaviors.
Showed a non-significant decrease in body weight that recovered by day 6.
Showed no significant differences in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels compared to controls.
Showed no significant organ damage in heart, liver, spleen, lung, or kidney tissues via histopathological analysis.

化学信息

分子量 459.49
分子式 C26H25N3O5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础